ctDNA analysis prior to the start of the 3rd line treatment revealed a KRAS and a TP53 mutation in both patients, whereas tumor tissue from the initial diagnosis was wild type for all genes analyzed (Figure 1B). Here, TP53 is linked to neoplasm.